B7-H4 Antibody, anti-human, REAfinity™
Synonyms: VTCN1, B7H4, B7h.5
RECOMBINANT EXTENDED VALIDATION
Clone:
REA1329 | MIH43
Type of antibody:
Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for B7-H4 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
PE
PE-Vio 615
PE-Vio 670
Vio Bright V423
Vio Bright V600
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-128-853, 130-128-767
Description:
A mixture of uncoated Latex beads and Latex beads coated with recombinant human B7-H4 protein was stained with B7-H4 antibodies or with the corresponding REA control (S) antibodies (left peak). Flow cytometry was performed with the MACSQuant® Analyzer.

Application imageView details view details

Application imageView details view details
Extended validation for B7-H4 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1329
MIH43
high
H74
low

Cells were incubated with an excess of purified unconjugated B7-H4 (REA1329) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for B7-H4. Human peripheral blood mononuclear cells (PBMCs) were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Transcription Factor Staining Buffer Set followed by intracellular staining with B7-H4 antibodies. As a control, B7-H4 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for B7-H4 Antibody, anti-human, REAfinity™
Overview

Clone REA1329 recognizes human B7-H4, a member of the B7 family of costimulatory proteins which is also known as VTCN1 (V-set domain-containing T-cell activation inhibitor 1). Expression of B7-H4 is found on antigen-presenting cells, that includes activated T and B cells, monocytes and dendritic cells. Overexpression is found in different cancers, including breast, ovarian, endometrial, renal cell (RCC) and non-small-cell lung cancers (NSCLC). B7-H4 functions as an immune checkpoint molecule.

Additional information: Clone REA1329 displays negligible binding to Fc receptors.

Alternative names

VTCN1, B7H4, B7h.5

Detailed product information

Technical specifications

Clone
REA1329
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Recombinant antibodies
Species reactivity
human
Antigen
B7-H4
Molecular mass of antigen [kDa]
28,4
Distribution of antigen
B cells, T cells, monocytes, dendritic cells, tumor cells
Entrez Gene ID

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for B7-H4 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for B7-H4 Antibody, anti-human, REAfinity™
Publications
  1. Sica, G. L. et al. (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18 (6): 849-861
  2. Wang, L. et al. (2016) Could B7-H4 serve as a target to activate anti-cancer immunity? Int. Immunopharmacol. 38: 97-103
  3. Leung, J. et al. (2013) Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. J Immunol 190 (12): 6651-6661

You have previously chosen International as your location.
What do you want to do?